Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.40 | -0.71% | -0.01 |
MRNS closed down 2.08 percent on Thursday, April 18, 2024, on 2.54 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Boomer Sell Setup | Bearish Swing Setup | -0.71% | |
| Calm After Storm | Range Contraction | -0.71% | |
| Narrow Range Bar | Range Contraction | -0.71% | |
| Lower Bollinger Band Walk | Weakness | -0.71% | |
| Inside Day | Range Contraction | -0.71% | |
| Wide Bands | Range Expansion | -0.71% | |
| Lower Bollinger Band Touch | Weakness | -0.71% | |
| Oversold Stochastic | Weakness | -0.71% | |
| Volume Surge | Other | -2.78% | |
| Calm After Storm | Range Contraction | -2.78% |
| Alert | Time |
|---|---|
| Possible NR7 | 22 minutes ago |
| Rose Above Previous Day's High | about 4 hours ago |
| 1.5x Volume Pace | about 4 hours ago |
| Up 5% | about 5 hours ago |
| Up 3% | about 5 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.26 |
| 52 Week Low | 1.11 |
| Average Volume | 1,903,728 |
| 200-Day Moving Average | 8.33 |
| 50-Day Moving Average | 8.57 |
| 20-Day Moving Average | 7.10 |
| 10-Day Moving Average | 5.33 |
| Average True Range | 0.86 |
| RSI (14) | 13.79 |
| ADX | 45.95 |
| +DI | 4.62 |
| -DI | 57.22 |
| Chandelier Exit (Long, 3 ATRs) | 6.92 |
| Chandelier Exit (Short, 3 ATRs) | 3.69 |
| Upper Bollinger Bands | 12.91 |
| Lower Bollinger Band | 1.28 |
| Percent B (%b) | 0.01 |
| BandWidth | 164.03 |
| MACD Line | -1.83 |
| MACD Signal Line | -1.01 |
| MACD Histogram | -0.8193 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.95 | ||||
| Resistance 3 (R3) | 1.93 | 1.73 | 1.86 | ||
| Resistance 2 (R2) | 1.73 | 1.59 | 1.74 | 1.83 | |
| Resistance 1 (R1) | 1.57 | 1.51 | 1.47 | 1.59 | 1.80 |
| Pivot Point | 1.37 | 1.37 | 1.32 | 1.38 | 1.37 |
| Support 1 (S1) | 1.21 | 1.23 | 1.11 | 1.23 | 1.02 |
| Support 2 (S2) | 1.01 | 1.15 | 1.02 | 0.99 | |
| Support 3 (S3) | 0.85 | 1.01 | 0.96 | ||
| Support 4 (S4) | 0.87 |
